Published in Cancer Res on August 15, 2005
Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood (2005) 1.84
Breakpoint sites disclose the role of the V(D)J recombination machinery in the formation of T-cell receptor (TCR) and non-TCR associated aberrations in T-cell acute lymphoblastic leukemia. Haematologica (2013) 1.08
Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology. Glia (2009) 0.96
Gene expression profiling of precursor T-cell lymphoblastic leukemia/lymphoma identifies oncogenic pathways that are potential therapeutic targets. Leukemia (2007) 0.93
A systematic enhancer screen using lentivector transgenesis identifies conserved and non-conserved functional elements at the Olig1 and Olig2 locus. PLoS One (2010) 0.93
LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways. PLoS One (2014) 0.91
Application of a new probabilistic model for mining implicit associated cancer genes from OMIM and medline. Cancer Inform (2007) 0.79
Integrative computational analysis of transcriptional and epigenetic alterations implicates DTX1 as a putative tumor suppressor gene in HNSCC. Oncotarget (2017) 0.75
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell (1991) 10.06
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res (1988) 9.96
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst (1991) 9.39
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64
Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity (1999) 5.34
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88
Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med (1996) 4.79
PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev (2001) 4.53
Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol (2003) 4.43
Sonic hedgehog--regulated oligodendrocyte lineage genes encoding bHLH proteins in the mammalian central nervous system. Neuron (2000) 4.17
Bethesda proposals for classification of lymphoid neoplasms in mice. Blood (2002) 4.07
Identification of a novel family of oligodendrocyte lineage-specific basic helix-loop-helix transcription factors. Neuron (2000) 3.91
Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Dev (2002) 3.55
E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas. Mol Cell Biol (1997) 3.10
The bHLH transcription factor Olig2 promotes oligodendrocyte differentiation in collaboration with Nkx2.2. Neuron (2001) 2.89
Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1. Mol Cell Biol (2000) 2.80
Olig2 and Ngn2 function in opposition to modulate gene expression in motor neuron progenitor cells. Genes Dev (2005) 2.40
Combinatorial roles of olig2 and neurogenin2 in the coordinated induction of pan-neuronal and subtype-specific properties of motoneurons. Neuron (2001) 2.37
Enhancer-binding activity of the tal-1 oncoprotein in association with the E47/E12 helix-loop-helix proteins. Mol Cell Biol (1991) 2.25
High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice. Mol Cell Biol (1997) 2.19
A requirement for Notch1 distinguishes 2 phases of definitive hematopoiesis during development. Blood (2004) 2.06
NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood (2005) 2.03
Dynamic expression of basic helix-loop-helix Olig family members: implication of Olig2 in neuron and oligodendrocyte differentiation and identification of a new member, Olig3. Mech Dev (2000) 2.00
The SCL gene product: a positive regulator of erythroid differentiation. EMBO J (1992) 1.90
Regionalization and fate specification in neurospheres: the role of Olig2 and Pax6. Mol Cell Neurosci (2004) 1.85
Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet (2004) 1.79
Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities. EMBO J (2003) 1.73
Analysis of gene expression in a complex differentiation hierarchy by global amplification of cDNA from single cells. Curr Biol (1995) 1.67
Thymic overexpression of Ttg-1 in transgenic mice results in T-cell acute lymphoblastic leukemia/lymphoma. Mol Cell Biol (1992) 1.62
Hematopoietic stem cells engraft in mice with absolute efficiency. Nat Immunol (2003) 1.55
Hematopoietic stem cells expand during serial transplantation in vivo without apparent exhaustion. Curr Biol (1997) 1.44
An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J (1997) 1.43
Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice. Mol Cell Biol (1999) 1.38
Notch oncoproteins depend on gamma-secretase/presenilin activity for processing and function. J Biol Chem (2004) 1.31
Spinal cord oligodendrocytes develop from ventrally derived progenitor cells that express PDGF alpha-receptors. Development (1996) 1.30
Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A (2001) 1.29
The E2A and tal-1 helix-loop-helix proteins associate in vivo and are modulated by Id proteins during interleukin 6-induced myeloid differentiation. Proc Natl Acad Sci U S A (1994) 1.27
Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol (2000) 1.26
Nuclear export of OLIG2 in neural stem cells is essential for ciliary neurotrophic factor-induced astrocyte differentiation. J Cell Biol (2004) 1.25
OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet (2001) 1.19
The t(14;21)(q11.2;q22) chromosomal translocation associated with T-cell acute lymphoblastic leukemia activates the BHLHB1 gene. Proc Natl Acad Sci U S A (2000) 1.08
Sonic hedgehog-dependent emergence of oligodendrocytes in the telencephalon: evidence for a source of oligodendrocytes in the olfactory bulb that is independent of PDGFRalpha signaling. Development (2001) 1.06
Defective development of thymocytes overexpressing the costimulatory molecule, heat-stable antigen. J Exp Med (1994) 1.03
OLIG-1 and 2 gene expression and oligodendroglial tumours. Neuropathol Appl Neurobiol (2002) 0.88
The heart LIM protein gene (Hlp), expressed in the developing and adult heart, defines a new tissue-specific LIM-only protein family. Mech Dev (2002) 0.82
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 8.33
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell (2009) 4.30
Hematopoietic competence is a rare property of neural stem cells that may depend on genetic and epigenetic alterations. Nat Med (2002) 3.94
Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell (2008) 3.87
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2004) 3.84
L3MBTL1, a histone-methylation-dependent chromatin lock. Cell (2007) 3.70
Representation is faithfully preserved in global cDNA amplified exponentially from sub-picogram quantities of mRNA. Nat Biotechnol (2002) 3.26
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol (2006) 2.51
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med (2008) 2.19
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet (2007) 2.18
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood (2004) 2.12
Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med (2004) 2.05
NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood (2005) 2.03
Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells. Proc Natl Acad Sci U S A (2007) 2.02
The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med (2010) 1.93
NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood (2011) 1.91
Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol (2002) 1.88
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood (2006) 1.88
Intermediate-term hematopoietic stem cells with extended but time-limited reconstitution potential. Cell Stem Cell (2010) 1.87
Scl regulates the quiescence and the long-term competence of hematopoietic stem cells. Blood (2009) 1.87
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw (2011) 1.85
Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell (2009) 1.84
Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood (2005) 1.84
The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood (2002) 1.84
In vitro and in vivo expansion of hematopoietic stem cells. Oncogene (2004) 1.83
The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells. Cancer Cell (2006) 1.83
The human L(3)MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL (ETV6). J Biol Chem (2003) 1.73
Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc Natl Acad Sci U S A (2004) 1.71
Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood (2003) 1.70
The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity (2002) 1.70
Asymmetric segregation and self-renewal of hematopoietic stem and progenitor cells with endocytic Ap2a2. Blood (2011) 1.65
An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell (2012) 1.61
Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood (2003) 1.59
Malignant brain tumor repeats: a three-leaved propeller architecture with ligand/peptide binding pockets. Structure (2003) 1.56
Hematopoietic stem cells engraft in mice with absolute efficiency. Nat Immunol (2003) 1.55
Impaired differentiation and apoptosis of hematopoietic precursors in a mouse model of myelodysplastic syndrome. Haematologica (2008) 1.54
Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res (2010) 1.53
An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity. Cell Stem Cell (2010) 1.52
Id1 restrains p21 expression to control endothelial progenitor cell formation. PLoS One (2007) 1.52
Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity. Genes Dev (2008) 1.51
The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science (2011) 1.49
Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. Leuk Res (2012) 1.47
Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. Genes Dev (2010) 1.42
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol (2003) 1.41
Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood (2011) 1.36
A novel role for STAT1 in regulating murine erythropoiesis: deletion of STAT1 results in overall reduction of erythroid progenitors and alters their distribution. Blood (2004) 1.34
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood (2004) 1.33
The role of NUP98 gene fusions in hematologic malignancy. Leuk Lymphoma (2004) 1.33
Isolation and characterization of runxa and runxb, zebrafish members of the runt family of transcriptional regulators. Exp Hematol (2002) 1.31
Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation. Cancer Res (2007) 1.30
Targeted disruption of Zfp36l2, encoding a CCCH tandem zinc finger RNA-binding protein, results in defective hematopoiesis. Blood (2009) 1.29
A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood (2009) 1.28
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica (2013) 1.27
L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. Proc Natl Acad Sci U S A (2010) 1.27
Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34+ cells. Blood (2002) 1.26
Retinoic acid signaling is essential for embryonic hematopoietic stem cell development. Cell (2013) 1.25
Chromosomal rearrangements leading to MLL gene fusions: clinical and biological aspects. Cancer Res (2008) 1.20
GATA-3 regulates the self-renewal of long-term hematopoietic stem cells. Nat Immunol (2013) 1.19
Chromosomal aberrations induced by double strand DNA breaks. DNA Repair (Amst) (2005) 1.19
Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol (2003) 1.18
Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol (2006) 1.17
AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. Proc Natl Acad Sci U S A (2005) 1.14
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res (2008) 1.14
Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model. Blood (2012) 1.14
Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant (2008) 1.13
The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior. Cell Cycle (2009) 1.13
Leukemic transformation in mice expressing a NUP98-HOXD13 transgene is accompanied by spontaneous mutations in Nras, Kras, and Cbl. Blood (2008) 1.12
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol (2010) 1.11
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant (2007) 1.10
ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation. Mol Cell Biol (2009) 1.09
Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Res (2014) 1.08
The p53 tumor suppressor protein regulates hematopoietic stem cell fate. J Cell Physiol (2011) 1.08
The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2. Mol Cell Biol (2006) 1.07
Expression of a CALM-AF10 fusion gene leads to Hoxa cluster overexpression and acute leukemia in transgenic mice. Cancer Res (2007) 1.07
Gradient of E2A activity in B-cell development. Mol Cell Biol (2002) 1.07
PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. Blood (2012) 1.07
Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. Sci Signal (2012) 1.06
AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches. Front Med (2012) 1.05
Chromatin remodeling complex NURF regulates thymocyte maturation. Genes Dev (2011) 1.05
The Stil protein regulates centrosome integrity and mitosis through suppression of Chfr. J Cell Sci (2011) 1.04
Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol (2004) 1.03
cDNAs generated from individual epidermal cells reveal that differential gene expression predicting subsequent resistance or susceptibility to rust fungal infection occurs prior to the fungus entering the cell lumen. Mol Plant Microbe Interact (2003) 1.02
Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 1.02